ArticleNature biotechnology2025
Trans-nuclease activity of Cas9 activated by DNA or RNA target binding.
Article in Nature biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Recent Advances in CRISPR/Cas Technologies for Biological Discovery, Therapeutics, and Diagnostics.Biomolecules · 2026Review
- CRISPR RNA architecture steers Cas9 catalysis and fidelity via a guide repeat clasp motif.Nucleic acids research · 2026Article
- Specific cleavage of 5' overhangs of non-target strand by Cas9 activated by target DNA binding.Nucleic acids research · 2026Article
- CRISPR diagnostics: from trans-nuclease activity to cancer diagnosis.Cell & bioscience · 2026Review
- DNA-guided CRISPR-Cas12 for cellular RNA targeting.Nature biotechnology · 2026Article
- AlphaFold3-guided tracrRNA redesign yields small monomeric Cas12f RNPs.Nucleic acids research · 2026Article
- Elimination of cis-cleavage in CRISPR diagnostics for one-pot rapid nucleic acid detection.Nucleic acids research · 2026Article
- Structural visualization of the molecular evolution of CRISPR-Cas9.Nature structural & molecular biology · 2026Article
- Revealing the multiple faces of LRG1: gene expression, structure, function, and therapeutic potential.Journal of advanced research · 2026Review
- CRISPR-Cas9 trans-cleavage is hindered by a flanked R-loop, an elongated spacer, and an inactive HNH domain.Nature communications · 2026Article
- An overview of CRISPR-artificial intelligence theranostics: Current and emerging applications.Biomaterials translational · 2026Review
- A guide RNA repeat checkpoint steers CRISPR-Cas9 catalysis.bioRxiv : the preprint server for biology · 2025Article
- LbuCas13a directly targets DNA and elicits strong trans-cleavage activity.Nature biomedical engineering · 2025Article
- Gene Surfing: An efficient and versatile tool for targeted enzyme mining in metagenomics.Synthetic and systems biotechnology · 2025Article
- CRISPR/Cas Technology for the Diagnosis of Animal Infectious Diseases.Microorganisms · 2025Review
- Cascade CRISPR/cas Enables More Sensitive Detection ofMicroorganisms · 2025Article
- From Code to Life: The AI-Driven Revolution in Genome Editing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Detection of tomato brown rugose fruit virus through CRISPR-Cas12a and CRISPR-Cas9 systems.Scientific reports · 2025Article
- The discovery of Cas9's trans-cleavage activity: Unlocking new molecular diagnostic tools.Clinical and translational medicine · 2025Article
- Virus Detection by CRISPR-Cas9-Mediated Strand Displacement in a Lateral Flow Assay.ACS applied bio materials · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Type V and type VI CRISPR-Cas systems have been shown to cleave nonspecific single-stranded DNA (ssDNA) or single-stranded RNA (ssRNA) in trans, but this has not been observed in type II CRISPR-Cas systems using single guide RNA. We show here that the type II CRISPR-Cas9 systems directed by CRISPR RNA and trans-activating CRISPR RNA dual RNAs show RuvC domain-dependent trans-cleavage activity for both ssDNA and ssRNA substrates. Cas9 possesses sequence preferences for trans-cleavage substrates, preferring to cleave T- or C-rich ssDNA substrates. We find that the trans-cleavage activity of Cas9 can be activated by target ssDNA, double-stranded DNA and ssRNA. The crystal structure of Cas9 in complex with guide RNA and target RNA provides a structural basis for the binding of target RNA to activate Cas9. Based on the trans-cleavage activity of Cas9 and nucleic acid amplification technology, we develop the nucleic acid detection platforms DNA-activated Cas9 detection and RNA-activated Cas9 detection, which are capable of detecting DNA and RNA samples with high sensitivity and specificity.
Indexed as
Identifiers
38811761What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.